Xyzagen’s founder and Principal Consultant, Christopher Crean, featured on the cover article for Pharmatech Outlook Bioanalytical Services Edition, November 2020
Pittsboro, NC –November 11, 2020
The pharmaceutical drug discovery industry is evolving. Innovations in the sector are more and more powered by seed, NIH, and VC-funded companies that are either spun out of academic institutions or are being incubated by venture capital firms based on licensed technology or public-private partnerships. In parallel, a wave of mergers and acquisitions is happening on the scientific operations and process side of pharmaceutical research due to the stability and growth of pharmaceutical outsourcing. CROs have been aggregating and thus expanding their service areas to be more of a single source provider within either testing, regulatory, or manufacturing. This narrowing field of nonclinical, clinical, bioanalytical, and manufacturing CROs that provide full support to large pharma are also looking to support the smaller innovators with their breadth of capabilities. These organizations are not just located within the US, and thus this reordering of “who does what” has also led to the expanded importance of individual consultants with scientific discipline expertise within the industry and the growing role of consultancy organizations that support early innovators navigating the changing regulatory and CRO landscape while also quickly advancing their client’s research program…..
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.
Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
